155 related articles for article (PubMed ID: 38560429)
61. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
Kupelian PA; Reddy CA; Carlson TP; Willoughby TR
Cancer J; 2002; 8(1):62-6. PubMed ID: 11895204
[TBL] [Abstract][Full Text] [Related]
62. Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
Cloitre M; Valerio M; Mampuya A; Rakauskas A; Berthold D; Tawadros T; Meuwly JY; Heym L; Duclos F; Vallet V; Zeverino M; Jichlinski P; Prior J; Roth B; Bourhis J; Herrera FG
Br J Radiol; 2023 Apr; 96(1145):20220803. PubMed ID: 36745031
[TBL] [Abstract][Full Text] [Related]
63. Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data.
Hervás-Morón A; Domínguez-Rullán J; Santana VD; Valero M; Vallejo C; Sancho S; Fuentes JDG; López-Campos F; Gallego MC
World J Clin Oncol; 2022 Jul; 13(7):652-662. PubMed ID: 36157159
[TBL] [Abstract][Full Text] [Related]
64. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
65. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
66. Treatment Tolerability and Toxicity of Postoperative Proton Beam Therapy for Gynecologic Malignancies: Results of the Prospective Phase 2 APROVE Trial.
Arians N; Lindel K; Krisam J; Oelmann-Avendano JT; Meixner E; König L; Hoerner-Rieber J; Wark A; Forster T; Weykamp F; Lang K; Schneeweiss A; Ellerbrock M; Mielke T; Herfarth K; Debus J
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):825-836. PubMed ID: 36642110
[TBL] [Abstract][Full Text] [Related]
67. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
68. A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.
Nakamura K; Ikeda I; Inokuchi H; Takayama K; Inoue T; Kamba T; Ogawa O; Hiraoka M; Mizowaki T
J Radiat Res; 2018 Sep; 59(5):656-663. PubMed ID: 30085048
[TBL] [Abstract][Full Text] [Related]
69. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
[TBL] [Abstract][Full Text] [Related]
70. A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis.
Callan L; Bauman G; Chen J; Lock M; Sexton T; D'Souza D; Rodrigues G
Adv Radiat Oncol; 2019; 4(4):668-673. PubMed ID: 31681864
[TBL] [Abstract][Full Text] [Related]
71. Multiparametric Magnetic Resonance Imaging- Guided Dose-Escalated Radiation Therapy for Localized Prostate Cancer: A Prospective Phase 2 Trial.
Camden N; Blumenfeld P; Roy S; Chowdhary M; King K; Shors S; Braun R; White G; Turian J; Wang D
Pract Radiat Oncol; 2024; 14(2):e132-e140. PubMed ID: 37923137
[TBL] [Abstract][Full Text] [Related]
72. Use of a Biodegradable, Contrast-Filled Rectal Spacer Balloon in Intensity-Modulated Radiotherapy for Intermediate-Risk Prostate Cancer Patients: Dosimetric Gains in the BioPro-RCMI-1505 Study.
Latorzeff I; Bruguière E; Bogart E; Le Deley MC; Lartigau E; Marre D; Pasquier D
Front Oncol; 2021; 11():701998. PubMed ID: 34513681
[TBL] [Abstract][Full Text] [Related]
73. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
74. Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) Techniques.
Tonetto F; Magli A; Moretti E; Guerini AE; Tullio A; Reverberi C; Ceschia T; Spiazzi L; Titone F; Prisco A; Signor MA; Buglione M; De Giorgi G; Trovò M; Triggiani L
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498488
[TBL] [Abstract][Full Text] [Related]
75. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.
Katz AJ; Santoro M; Diblasio F; Ashley R
Radiat Oncol; 2013 May; 8():118. PubMed ID: 23668632
[TBL] [Abstract][Full Text] [Related]
76. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
77. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
78. High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.
Marotte D; Gal J; Schiappa R; Gautier M; Boulahssass R; Chand-Fouche ME; Hannoun-Levi JM
Clin Transl Radiat Oncol; 2022 Jul; 35():104-109. PubMed ID: 35692263
[TBL] [Abstract][Full Text] [Related]
79. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(27):1-118. PubMed ID: 23074405
[TBL] [Abstract][Full Text] [Related]
80. Preliminary analysis for integration of spot-scanning proton beam therapy and real-time imaging and gating.
Shimizu S; Matsuura T; Umezawa M; Hiramoto K; Miyamoto N; Umegaki K; Shirato H
Phys Med; 2014 Jul; 30(5):555-8. PubMed ID: 24786663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
